Compositions and methods for silencing hepatitis B virus gene expression
US10415037B2 · kind B2 · utility
7Cited by
1References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 1, 2015 |
| Grant date | Sep 17, 2019 |
| Priority date | — |
| Expiry date | Oct 1, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/323
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides compositions comprising therapeutic nucleic acids such as siRNA that target Hepatitis B virus (HBV) gene expression, lipid particles comprising one or more (e.g., a combination) of the therapeutic nucleic acids, and methods of delivering and/or administering the lipid particles (e.g., for treating HBV infection and/or HDV infection in humans).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.